The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is the third most common cause of death from cancer in men of all ages. It is rare in men younger than 40.
Levels of a substance called prostate specific antigen (PSA) is often high in men with prostate cancer. However, PSA can also be high with other prostate conditions. Since the PSA test became common, most prostate cancers are found before they cause symptoms. Symptoms of prostate cancer may include
Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
Low back pain
Pain with ejaculation
Prostate cancer treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Treatment may include surgery, radiation therapy, chemotherapy or control of hormones that affect the cancer.
ScienceDaily (July 2, 2006) - Drinking an eight ounce glass of pomegranate juice daily increased by nearly four times the period during which PSA levels in men treated for prostate cancer remained stable, a three-year UCLA study has found.
Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
Woo TC, Choo R, Jamieson M, Chander S, Vieth R.
Nutr Cancer. 2005;51(1):32-6.
PMID: 15749627
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.
Clin Cancer Res. 2006 Jul 1;12(13):4018-26.
PMID: 16818701
A chemical found in green tea appears to slow the progression of prostate cancer, a study has suggested.
Green tea has been linked to a positive effect on a wide range of conditions, including heart disease, cancer and Alzheimer's disease.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
PMID: 18645193
DOI: 10.1200/JCO.2007.15.9749